Spore.Bio, a DeepTech startup pioneering AI-driven microbiology testing, has secured €22 million in a Series A funding round to enhance quality control in manufacturing. This investment follows a €7.9 million pre-Seed round led by LocalGlobe in December 2023, bringing the total funding raised to €29.9 million.
Founded in 2023, Spore.Bio was established by three industry experts: CEO Amine Raji, a food and beverage manufacturing engineer with six years of experience at Nestlé factories; CTO Maxime Mistretta, a microbiology PhD graduate and postdoc from the Pasteur Institute; and COO Mohamed Tazi, a second-time entrepreneur who previously sold his company Gymlib to EGYM.
The company has developed a proprietary AI-based technology that delivers immediate, on-site microbiological testing. Unlike conventional tests, which can take anywhere from five to 20 days and require samples to be sent to external laboratories, Spore.Bio’s solution provides real-time insights. Its device uses advanced machine learning models to measure bacterial concentrations in various industries, including food, beverages, pharmaceuticals, and cosmetics. Quality managers can quickly detect potential risks using the company’s internally developed dashboard, ensuring greater traceability and transparency.
Spore.Bio has also strengthened its position by acquiring Greentropism, a competitor that previously raised €3 million. This acquisition will help the company leverage Greentropism’s technical expertise and intellectual property.
CEO and Co-founder Amine Raji highlighted the impact of AI in transforming scientific industries. “AI is nice for chatbots and LLMs, but some amazing, niche applications are paving the way of deep changes in certain industries, especially science-related industries. We are proud of being an example of it, while having developed in only one year our proprietary AI-based technology that manages to do what existing technologies couldn’t for two centuries. We will keep on fighting to pursue our one and only goal: make every consumer product safe all around the world using our technology.”
The company’s breakthrough technology is already gaining traction beyond the food and beverage sector, extending into pharmaceuticals and cosmetics. Investors see strong potential in Spore.Bio’s ability to redefine the speed, precision, and scalability of microbiological testing.
Raffi Kamber, General Partner at Singular, commented on the company’s expansion. “Originally developed for the Food & Beverage sector, Spore.bio is now also reshaping microbiological detection in pharmaceuticals and cosmetics. With a founding team that blends research and industrial expertise, it is redefining speed, precision, and scalability setting new standards. We are confident it will be a driving force in the future of integrated testing across industries and are excited to support and witness this transformation.”
With its fresh funding and strategic acquisition, Spore.Bio is set to advance its AI-driven technology, making microbiological testing faster, more precise, and more accessible across multiple industries.
